IO Biotech
- Country
- 🇩🇰Denmark
- Ownership
- -
- Employees
- 68
- Market Cap
- $104.7M
- Introduction
IO Biotech, Inc. engages in the development of immune modulating cancer therapies based on its T-win technology platform. Its platform is a novel approach to cancer immunotherapy designed to activate naturally occurring T cells to target immunosuppressive mechanisms. The company was founded by Mai-Britt Zocca, Inge Marie Svane, and Mads Hald Andersen in December 2014 and is headquartered in Copenhagen, Denmark.
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
- Conditions
- MelanomaSquamous Cell Carcinoma of Head and Neck
- Interventions
- Drug: IO102-IO103Drug: Pembrolizumab KEYTRUDA®
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- IO Biotech
- Target Recruit Count
- 60
- Registration Number
- NCT05280314
- Locations
- 🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
🇺🇸Massey Cancer Center, Richmond, Virginia, United States
🇩🇰Aarhus University Hospital, Aarhus, Denmark
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)
- Conditions
- Metastatic MelanomaUnresectable Melanoma
- Interventions
- Drug: IO102-IO103Drug: Pembrolizumab
- First Posted Date
- 2021-12-13
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- IO Biotech
- Target Recruit Count
- 407
- Registration Number
- NCT05155254
- Locations
- 🇳🇱
Erasmus MC, Rotterdam, Netherlands
🇦🇺Flinders Medical Centre, Bedford Park, South Australia, Australia
🇩🇰Herlev og Gentofte Hospital, Herlev, Denmark
IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC
- Conditions
- Lung Cancer Non Small CellHead and Neck Squamous Cell CarcinomaUrothelial Carcinoma Bladder
- Interventions
- First Posted Date
- 2021-10-14
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- IO Biotech
- Target Recruit Count
- 63
- Registration Number
- NCT05077709
- Locations
- 🇺🇸
University of California San Diego, San Diego, California, United States
🇬🇧Velindre Cancer Center, Cardiff, United Kingdom
🇺🇸City of Hope, Duarte, California, United States
IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC
- Conditions
- NSCLC
- Interventions
- Biological: IO102Biological: pembrolizumab (Keytruda)Drug: Carboplatin (Carboplatin Kabi)Drug: Pemetrexed (Pemetrexed Alvogen)
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2022-04-21
- Lead Sponsor
- IO Biotech
- Target Recruit Count
- 109
- Registration Number
- NCT03562871
- Locations
- 🇪🇸
Insituto Oncologico Dr Rosell. Hospital Universitario Quiron Dexeus, Barcelona, Catalonia, Spain
🇪🇸Hospital Universitario de Vall d'Hebron, Barcelona, Catalonia, Spain
🇳🇱Stichting Het Nederlands Kanker Instituut, Amsterdam, Community Of Amsterdam, Netherlands